STORY SUMMARY

FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma

The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced, refractory melanoma.

This is a brief summary of reporting from FDA Press Releases. Read the original for the full article and context.

Read original reporting ↗

More from FDA Press Releases · Latest headlines